Stocks of Ionis Pharmaceuticals - Current price, Where to buy? Chart
| Detail | Data |
|---|---|
| Stocks: | Ionis Pharmaceuticals |
| ompany Name: | Ionis Pharmaceuticals, Inc. |
| Ticker: | IONS |
| Exchange: | NasdaqGS |
| Outstanding stocks: | 145,846,000 |
| 24-hour Volume: | 1,212,393 |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Number of Employees: | 927 |
| Country: | United States |
| City: | Carlsbad |
| Address: | 2855 Gazelle Court |
| P/E Ratio: | Forward P/E | EPS: | Forward EPS | Book value per share | Market capitalization |
|---|---|---|---|---|---|
| / | -12.99 | -2.56 USD | -3.23 USD | 2.68 USD | 6,121,156,608.00 USD |
| P/E Ratio: | / |
|---|---|
| Forward P/E: | -12.99 |
| EPS: | -2.56 USD |
| Forward EPS: | -3.23 |
| Book value per share: | 2.68 USD |
| Market capitalization: | 6,121,156,608.00 USD |
Ionis Pharmaceuticals
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | 787,646,976.00 USD |
| Net Income: | -366,286,016.00 USD |
| Price-to-Book (P/B) Ratio: | 15.67 |
| PEG Ratio: | 0.21 |
Note: The data is approximate, subject to change over time, and may not be current; however, we strive for the highest possible accuracy.
Analysts' predictions
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation issued for Ionis Pharmaceuticals stocks is: buy |
| Number of Analysts: | 22 |
| Highest Target Price: | 85 USD |
| Lowest Target Price: | 29 USD |
| Average Target Price: | 59 USD |
Note: The data is approximate. Recommendations and price forecasts for Ionis Pharmaceuticals stocks based on analysts' ratings may change over time. Some recommendations may already be outdated and may not be accurate. We strongly advise against buying and selling stocks based on analysts' recommendations!
Dividend
| Dividends | Value |
|---|---|
| Dividend Amount | According to our data, the company Ionis Pharmaceuticals is currently not paying dividends. |
| Annual Yield %: | - |
| Ex-dividend Date: | - |
| Average % Yield for 5 Years: | - |
| Payout Ratio: | - |
| Value of Last Dividend Paid: | - |
| Date of Last Dividend: | - |
The dividend is displayed for the entire calendar year, however, it is usually paid out quarterly in parts. Data may change!
Where to Buy Ionis Pharmaceuticals Stocks?
If you're interested in investing in Ionis Pharmaceuticals stocks and believe in their future growth, you can purchase them through stock brokers like XTB or eToro. To make buying easier, we've prepared a table with offers from these brokers, including quick purchase of Ionis Pharmaceuticals stocks through mobile apps with client support. In this table, you can compare brokers offering real Ionis Pharmaceuticals stocks. Brokers providing the option to buy real stocks (not CFDs) are identified by "Real Stocks" in the comparison table column.
| Broker | Platforms | Regulation | Min. Deposit | Deposits / Withdrawals | CopyTrader | Real Stocks | Website Link |
|---|---|---|---|---|---|---|---|
 |
Proprietary platform, social network + CopyTrader™ | 100 USD | Bank transfer, credit cards, Skrill, PayPal, Neteller |
 Go to eToro
|
|||
 |
xStation, mobile version | 10 USD | Credit cards, Skrill, bank transfer |
 Go to XTB
|
|
|
| xStation, mobile version | Proprietary platform, social network + CopyTrader™ |
|
Go to XTB
|
Go to eToro
|
More Information about Ionis Pharmaceuticals (IONS)
Revenues of 787,646,976.00 USD indicate room for growth and improvement for Ionis Pharmaceuticals. This presents an opportunity for further development. Negative EBITDA of -319,217,984.00 USD may indicate challenges but also opportunities for Ionis Pharmaceuticals to invest in future growth. A higher debt-to-equity ratio of 5.09 indicates higher leverage for Ionis Pharmaceuticals compared to its equity, requiring cautious management. Gross margin of -15.17% indicates room for Ionis Pharmaceuticals to improve cost efficiency and competitiveness. Lower profit margin of -46.50% suggests opportunities for Ionis Pharmaceuticals to increase efficiency and reduce costs.
| Indicator | Value |
|---|---|
| Revenue, Debt, and Cash Flow | |
| Company Revenue: | 787,646,976.00 USD |
| EBITDA: | -319,217,984.00 USD - Negative EBITDA may signal financial challenges or growth investments. |
| Earnings Per Share: | -2.56 USD |
| Book Value Per Share: | 2.68 USD |
| Total Cash: | 2,337,501,952.00 USD |
| Total Cash per Share: | 16.04 USD |
| Total Debt: | 1,967,275,008.00 USD |
| Debt to Equity Ratio: | 5.09 |
| Quick Ratio: | 5.44 |
| Current Ratio: | 5.90 |
| Free Cash Flow: | -159,991,744.00 USD |
| Operating Cash Flow: | -307,512,992.00 USD |
| Company Margins | |
| Gross Margins: | -15.17 % |
| EBITDA Margins: | -40.53 % |
| Operating Margins: | 4.79 % |
| Profit Margins: | -46.50 % |
| Performance | |
| Return on Assets: | -7.5 % |
| Return on Equity: | -76.3 % |
| Earnings Growth (1 year): | / |
| Revenue Growth (1 year): | 113.6 % |
| Year-over-Year Quarterly Earnings Growth: | / |
| Valuation | |
| Market Capitalization: | 6,121,156,608.00 USD |
| Enterprise Value: | 5,910,217,728.00 USD |
| EV/Revenue: | 7.504 |
| EV/EBITDA: | -18.515 |
| Number of Shares and Short Shares | |
| Float Shares: | 144,524,567 shares |
| Shares Outstanding: | 145,846,000 shares |
| Held Percent Insiders: | 0.01 % |
| Held Percent Institutions: | 100.48 % |
| Shares Short: | 9,534,366 |
| Shares Short Prior Month: | 9,665,680 |
| Date Short Interest: | 2024-04-15 |
| Shares Percent Shares Out: | 6.54 % |
| Short Ratio: | 10.16 |
| Beta: | 0.40 |
| Short Percent of Float: | 7.74 % |
| Předpokládaný počet akcií: | 145,846,000 |
Frequently Asked Questions (FAQ)
According to our data, Ionis Pharmaceuticals does not currently pay dividends, even in 2024.
Ionis Pharmaceuticals shares are traded on the stock exchange NasdaqGS under the ticker symbol: IONS. You can buy or trade them with a variety of stock brokers offering real stock trading services.
According to our data, there is a buy recommendation issued for Ionis Pharmaceuticals shares by a total of 22 analysts. The average target price prediction is 59 USD per share.
The total number of Ionis Pharmaceuticals shares on the exchange is 145,846,000.00, which, at the current market capitalization, values the company at 6,121,156,608.00 USD.
